Activation of MyD88-dependent TLR1/2 signaling by misfolded α-synuclein, a protein linked to neurodegenerative disorders

Science Signaling

Volumn 8, Issue 376, 2015, Pages

  Daniele, Stefano G ^a   Béraud, Dawn ^a   Davenport, Connor ^a   Cheng, Kui ^b,c   Yin, Hang ^b,c   Maguire Zeiss, Kathleen A ^a  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c TSINGHUA UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; CANDESARTAN HEXETIL; CU CPT22; HETERODIMER; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; MYELOID DIFFERENTIATION FACTOR 88; OLIGOMER; TOLL LIKE RECEPTOR 1; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR AFFECTING AGENT; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; MYD88 PROTEIN, HUMAN; MYD88 PROTEIN, MOUSE; SNCA PROTEIN, HUMAN; SNCA PROTEIN, MOUSE; TLR2 PROTEIN, HUMAN; TLR2 PROTEIN, MOUSE;

ANIMAL CELL; ARTICLE; CELL MEMBRANE; DEGENERATIVE DISEASE; DRUG MECHANISM; MICROGLIA; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN FOLDING; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; ANIMAL; DIFFUSE LEWY BODY DISEASE; GENETICS; HEK293 CELL LINE; HUMAN; METABOLISM; PARKINSON DISEASE; PROTEOSTASIS DEFICIENCY; SIGNAL TRANSDUCTION;

ALPHA-SYNUCLEIN; ANIMALS; HEK293 CELLS; HUMANS; LEWY BODY DISEASE; MICE; MYELOID DIFFERENTIATION FACTOR 88; PARKINSON DISEASE; PROTEIN FOLDING; PROTEOSTASIS DEFICIENCIES; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 1; TOLL-LIKE RECEPTOR 2;

EID: 84929619164     PISSN: 19450877     EISSN: 19379145     Source Type: Journal    
DOI: 10.1126/scisignal.2005965     Document Type: Article

References (128)

1. M. G. Spillantini, R. A. Crowther, R. Jakes, M. Hasegawa, M. Goedert, α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies. Proc. Natl. Acad. Sci. U. S. A. 95, 6469-6473 (1998).
2. A. Athanassiadou, G. Voutsinas, L. Psiouri, E. Leroy, M. H. Polymeropoulos, A. Ilias, G. M. Maniatis, T. Papapetropoulos, Genetic analysis of families with Parkinson disease that carry the Ala53Thr mutation in the gene encoding α-synuclein. Am. J. Hum. Genet. 65, 555-558 (1999).
3. R. Krüger, W. Kuhn, T. Müller, D. Woitalla, M. Graeber, S. Kosel, H. Przuntek, J. T. Epplen, L. Schöls, O. Riess, Ala30Pro mutation in the gene encoding α-synuclein in Parkinson's disease. Nat. Genet. 18, 106-108 (1998).
4. M. H. Polymeropoulos, J. J. Higgins, L. I. Golbe, W. G. Johnson, S. E. Ide, G. Di Iorio, G. Sanges, E. S. Stenroos, L. T. Pho, A. A. Schaffer, A. M. Lazzarini, R. L. Nussbaum, R. C. Duvoisin, Mapping of a gene for Parkinson's disease to chromosome 4q21-q23. Science 274, 1197-1199 (1996).
5. M. H. Polymeropoulos, C. Lavedan, E. Leroy, S. E. Ide, A. Dehejia, A. Dutra, B. Pike, H. Root, J. Rubenstein, R. Boyer, E. S. Stenroos, S. Chandrasekharappa, A. Athanassiadou, T. Papapetropoulos, W. G. Johnson, A. M. Lazzarini, R. C. Duvoisin, G. Di Iorio, L. I. Golbe, R. L. Nussbaum, Mutation in the α-synuclein gene identified in families with Parkinson's disease. Science 276, 2045-2047 (1997).
6. A. B. Singleton, M. Farrer, J. Johnson, A. Singleton, S. Hague, J. Kachergus, M. Hulihan, T. Peuralinna, A. Dutra, R. Nussbaum, S. Lincoln, A. Crawley, M. Hanson, D. Maraganore, C. Adler, M. R. Cookson, M. Muenter, M. Baptista, D. Miller, J. Blancato, J. Hardy, K. Gwinn-Hardy, α-Synuclein locus triplication causes Parkinson's disease. Science 302, 841 (2003).
7. W. Satake, Y. Nakabayashi, I. Mizuta, Y. Hirota, C. Ito, M. Kubo, T. Kawaguchi, T. Tsunoda, M. Watanabe, A. Takeda, H. Tomiyama, K. Nakashima, K. Hasegawa, F. Obata, T. Yoshikawa, H. Kawakami, S. Sakoda, M. Yamamoto, N. Hattori, M. Murata, Y. Nakamura, T. Toda, Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease. Nat. Genet. 41, 1303-1307 (2009).
8. S. W. Scholz, H. Houlden, C. Schulte, M. Sharma, A. Li, D. Berg, A. Melchers, R. Paudel, J. R. Gibbs, J. Simon-Sanchez, C. Paisan-Ruiz, J. Bras, J. Ding, H. Chen, B. J. Traynor, S. Arepalli, R. R. Zonozi, T. Revesz, J. Holton, N. Wood, A. Lees, W. Oertel, U. Wüllner, S. Goldwurm, M. T. Pellecchia, T. Illig, O. Riess, H. H. Fernandez, R. L. Rodriguez, M. S. Okun, W. Poewe, G. K. Wenning, J. A. Hardy, A. B. Singleton, F. Del Sorbo, S. Schneider, K. P. Bhatia, T. Gasser, SNCA variants are associated with increased risk for multiple system atrophy. Ann. Neurol. 65, 610-614 (2009).
9. J. Simón-Sánchez, C. Schulte, J. M. Bras, M. Sharma, J. R. Gibbs, D. Berg, C. Paisan-Ruiz, P. Lichtner, S. W. Scholz, D. G. Hernandez, R. Krüger, M. Federoff, C. Klein, A. Goate, J. Perlmutter, M. Bonin, M. A. Nalls, T. Illig, C. Gieger, H. Houlden, M. Steffens, M. S. Okun, B. A. Racette, M. R. Cookson, K. D. Foote, H. H. Fernandez, B. J. Traynor, S. Schreiber, S. Arepalli, R. Zonozi, K. Gwinn, M.van Der Brug, G. Lopez, S. J. Chanock, A. Schatzkin, Y. Park, A. Hollenbeck, J. Gao, X. Huang, N. W. Wood, D. Lorenz, G. Deuschl, H. Chen, O. Riess, J. A. Hardy, A. B. Singleton, T. Gasser, Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat. Genet. 41, 1308-1312 (2009).
10. K. A. Conway, J. D. Harper, P. T. Lansbury, Accelerated in vitro fibril formation by a mutant α-synuclein linked to early-onset Parkinson disease. Nat. Med. 4, 1318-1320 (1998).
11. N. Cremades, S. I. Cohen, E. Deas, A. Y. Abramov, A. Y. Chen, A. Orte, M. Sandal, R. W. Clarke, P. Dunne, F. A. Aprile, C. W. Bertoncini, N. W. Wood, T. P. Knowles, C. M. Dobson, D. Klenerman, Direct observation of the interconversion of normal and toxic forms of α-synuclein. Cell 149, 1048-1059 (2012).
12. H. A. Lashuel, C. R. Overk, A. Oueslati, E. Masliah, The many faces of α-synuclein: From structure and toxicity to therapeutic target. Nat. Rev. Neurosci. 14, 38-48 (2013).
13. A. Oueslati, M. Fournier, H. A. Lashuel, Role of post-translational modifications in modulating the structure, function and toxicity of α-synuclein: Implications for Parkinson's disease pathogenesis and therapies. Prog. Brain Res. 183, 115-145 (2010).
14. G. Taschenberger, M. Garrido, Y. Tereshchenko, M. Bähr, M. Zweckstetter, S. Kügler, Aggregation of αSynuclein promotes progressive in vivo neurotoxicity in adult rat dopaminergic neurons. Acta Neuropathol. 123, 671-683 (2012).
15. I. F. Tsigelny, Y. Sharikov, M. A. Miller, E. Masliah, Mechanism of alpha-synuclein oligomerization and membrane interaction: Theoretical approach to unstructured proteins studies. Nanomedicine 4, 350-357 (2008).
16. V. N. Uversky, Mysterious oligomerization of the amyloidogenic proteins. FEBS J. 277, 2940-2953 (2010).
17. E. Biasini, L. Fioriti, I. Ceglia, R. Invernizzi, A. Bertoli, R. Chiesa, G. Forloni, Proteasome inhibition and aggregation in Parkinson's disease: A comparative study in untransfected and transfected cells. J. Neurochem. 88, 545-553 (2004).
18. E. Emmanouilidou, L. Stefanis, K. Vekrellis, Cell-produced α-synuclein oligomers are targeted to, and impair, the 26S proteasome. Neurobiol. Aging 31, 953-968 (2010).
19. L. R. Feng, H. J. Federoff, S. Vicini, K. A. Maguire-Zeiss, α-Synuclein mediates alterations in membrane conductance: A potential role for α-synuclein oligomers in cell vulnerability. Eur. J. Neurosci. 32, 10-17 (2010).
20. E. Masliah, E. Rockenstein, I. Veinbergs, M. Mallory, M. Hashimoto, A. Takeda, Y. Sagara, A. Sisk, L. Mucke, Dopaminergic loss and inclusion body formation in α-synuclein mice: Implications for neurodegenerative disorders. Science 287, 1265-1269 (2000).
21. M. Xilouri, T. Vogiatzi, K. Vekrellis, D. Park, L. Stefanis, Abberant α-synuclein confers toxicity to neurons in part through inhibition of chaperone-mediated autophagy. PLOS One 4, e5515 (2009).
22. E. Emmanouilidou, K. Melachroinou, T. Roumeliotis, S. D. Garbis, M. Ntzouni, L. H. Margaritis, L. Stefanis, K. Vekrellis, Cell-produced α-synuclein is secreted in a calcium-dependent manner by exosomes and impacts neuronal survival. J. Neurosci. 30, 6838-6851 (2010).
23. A. Jang, H. J. Lee, J. E. Suk, J. W. Jung, K. P. Kim, S. J. Lee, Non-classical exocytosis of α-synuclein is sensitive to folding states and promoted under stress conditions. J. Neurochem. 113, 1263-1274 (2010).
24. H. J. Lee, S. Patel, S. J. Lee, Intravesicular localization and exocytosis of α-synuclein and its aggregates. J. Neurosci. 25, 6016-6024 (2005).
25. H. J. Lee, J. E. Suk, E. J. Bae, J. H. Lee, S. R. Paik, S. J. Lee, Assembly-dependent endocytosis and clearance of extracellular a-synuclein. Int. J. Biochem. Cell Biol. 40, 1835-1849 (2008).
26. H.-J. Lee, J.-E. Suk, C. Patrick, E.-J. Bae, J.-H. Cho, S. Rho, D. Hwang, E. Masliah, S.-J. Lee, Direct transfer of α-synuclein from neuron to astroglia causes inflammatory responses in synucleinopathies. J. Biol. Chem. 285, 9262-9272 (2010).
27. K. M. Danzer, W. P. Ruf, P. Putcha, D. Joyner, T. Hashimoto, C. Glabe, B. T. Hyman, P. J. McLean, Heat-shock protein 70 modulates toxic extracellular α-synuclein oligomers and rescues trans-synaptic toxicity. FASEB J. 25, 326-336 (2011).
28. K. M. Danzer, L. R. Kranich, W. P. Ruf, O. Cagsal-Getkin, A. R. Winslow, L. Zhu, C. R. Vanderburg, P. J. McLean, Exosomal cell-to-cell transmission of alpha synuclein oligomers. Mol. Neurodegener. 7, 42 (2012).
29. E. Angot, J. A. Steiner, C. M. Lema Tomé, P. Ekström, B. Mattsson, A. Björklund, P. Brundin, Alpha-synuclein cell-to-cell transfer and seeding in grafted dopaminergic neurons in vivo. PLOS One 7, e39465 (2012).
30. E. J. Bae, H. J. Lee, E. Rockenstein, D. H. Ho, E. B. Park, N. Y. Yang, P. Desplats, E. Masliah, S. J. Lee, Antibody-aided clearance of extracellular α-synuclein prevents cell-to-cell aggregate transmission. J. Neurosci. 32, 13454-13469 (2012).
31. P. Brundin, R. Melki, R. Kopito, Prion-like transmission of protein aggregates in neurodegenerative diseases. Nat. Rev. Mol. Cell Biol. 11, 301-307 (2010).
32. P. Desplats, H. J. Lee, E. J. Bae, C. Patrick, E. Rockenstein, L. Crews, B. Spencer, E. Masliah, S. J. Lee, Inclusion formation and neuronal cell death through neuronto-neuron transmission of α-synuclein. Proc. Natl. Acad. Sci. U. S. A. 106, 13010-13015 (2009).
33. S. J. Lee, P. Desplats, H. J. Lee, B. Spencer, E. Masliah, Cell-to-cell transmission of α-synuclein aggregates. Methods Mol. Biol. 849, 347-359 (2012).
34. S. H. Appel, Inflammation in Parkinson's disease: Cause or consequence? Mov. Disord. 27, 1075-1077 (2012).
35. E. C. Hirsch, S. Hunot, Neuroinflammation in Parkinson's disease: A target for neuroprotection? Lancet Neurol. 8, 382-397 (2009).
36. E. C. Hirsch, S. Vyas, S. Hunot, Neuroinflammation in Parkinson's disease. Parkinsonism Relat. Disord. 18(Suppl. 1), S210-S212 (2012).
37. O. Marques, T. F. Outeiro, Alpha-synuclein: From secretion to dysfunction and death. Cell Death Dis. 3, e350 (2012).
38. A. D. Reynolds, J. G. Glanzer, I. Kadiu, M. Ricardo-Dukelow, A. Chaudhuri, P. Ciborowski, R. Cerny, B. Gelman, M. P. Thomas, R. L. Mosley, H. E. Gendelman, Nitrated alphasynuclein-activated microglial profiling for Parkinson's disease. J. Neurochem. 104, 1504-1525 (2008).
39. 11C]-PK11195 PET. Mov. Disord. 22, 1852-1856 (2007).
40. 11C]PK11195 and positron emission tomography in patients after ischemic stroke. Neuroreport 11, 2957-2960 (2000).
41. Y. Ouchi, S. Yagi, M. Yokokura, M. Sakamoto, Neuroinflammation in the living brain of Parkinson's disease. Parkinsonism Relat. Disord. 15(Suppl. 3), S200-S204 (2009).
42. Y. Ouchi, E. Yoshikawa, Y. Sekine, M. Futatsubashi, T. Kanno, T. Ogusu, T. Torizuka, Microglial activation and dopamine terminal loss in early Parkinson's disease. Ann. Neurol. 57, 168-175 (2005).
43. D. Blum-Degen, T. Müller, W. Kuhn, M. Gerlach, H. Przuntek, P. Riederer, Interleukin-1β and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients. Neurosci. Lett. 202, 17-20 (1995).
44. G. Boka, P. Anglade, D. Wallach, F. Javoy-Agid, Y. Agid, E. C. Hirsch, Immunocytochemical analysis of tumor necrosis factor and its receptors in Parkinson's disease. Neurosci. Lett. 172, 151-154 (1994).
45. S. Hunot, N. Dugas, B. Faucheux, A. Hartmann, M. Tardieu, P. Debré, Y. Agid, B. Dugas, E. C. Hirsch, FcεRII/CD23 is expressed in Parkinson's disease and induces, in vitro, production of nitric oxide and tumor necrosis factor-α in glial cells. J. Neurosci. 19, 3440-3447 (1999).
46. M. Mogi, M. Harada, T. Kondo, P. Riederer, H. Inagaki, M. Minami, T. Nagatsu, Interleukin-1β, interleukin-6, epidermal growth factor and transforming growth factor-α are elevated in the brain from parkinsonian patients. Neurosci. Lett. 180, 147-150 (1994).
47. M. Mogi, M. Harada, P. Riederer, H. Narabayashi, K. Fujita, T. Nagatsu, Tumor necrosis factor-α (TNF-α) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients. Neurosci. Lett. 165, 208-210 (1994).
48. D. Béraud, H. A. Hathaway, J. Trecki, S. Chasovskikh, D. A. Johnson, J. A. Johnson, H. J. Federoff, M. Shimoji, T. R. Mhyre, K. A. Maguire-Zeiss, Microglial activation and antioxidant responses induced by the Parkinson's disease protein α-synuclein. J. Neuroimmune Pharmacol. 8, 94-117 (2013).
49. D. Beraud, K. A. Maguire-Zeiss, Misfolded α-synuclein and toll-like receptors: Therapeutic targets for Parkinson's disease. Parkinsonism Relat. Disord. 18(Suppl. 1), S17-S20 (2012).
50. D. Beraud, M. Twomey, B. Bloom, A. Mittereder, V. Ton, K. Neitzke, S. Chasovskikh, T. R. Mhyre, K. A. Maguire-Zeiss, α-Synuclein alters toll-like receptor expression. Front. Neurosci. 5, 80 (2011).
51. X. Su, H. J. Federoff, K. A. Maguire-Zeiss, Mutant α-synuclein overexpression mediates early proinflammatory activity. Neurotox. Res. 16, 238-254 (2009).
52. X. Su, K. A. Maguire-Zeiss, R. Giuliano, L. Prifti, K. Venkatesh, H. J. Federoff, Synuclein activates microglia in a model of Parkinson's disease. Neurobiol. Aging 29, 1690-1701 (2008).
53. S. Theodore, S. Cao, P. J. McLean, D. G. Standaert, Targeted overexpression of human α-synuclein triggers microglial activation and an adaptive immune response in a mouse model of Parkinson disease. J. Neuropathol. Exp. Neurol. 67, 1149-1158 (2008).
54. W. Zhang, T. Wang, Z. Pei, D. S. Miller, X. Wu, M. L. Block, B. Wilson, W. Zhang, Y. Zhou, J. S. Hong, J. Zhang, Aggregated α-synuclein activates microglia: A process leading to disease progression in Parkinson's disease. FASEB J. 19, 533-542 (2005).
55. L. Fellner, R. Irschick, K. Schanda, M. Reindl, L. Klimaschewski, W. Poewe, G. K. Wenning, N. Stefanova, Toll-like receptor 4 is required for α-synuclein dependent activation of microglia and astroglia. Glia 61, 349-360 (2013).
56. G. Y. Chen, G. Nuñez, Sterile inflammation: Sensing and reacting to damage. Nat. Rev. Immunol. 10, 826-837 (2010).
57. P. Duewell, H. Kono, K. J. Rayner, C. M. Sirois, G. Vladimer, F. G. Bauernfeind, G. S. Abela, L. Franchi, G. Nuñez, M. Schnurr, T. Espevik, E. Lien, K. A. Fitzgerald, K. L. Rock, K. J. Moore, S. D. Wright, V. Hornung, E. Latz, NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 464, 1357-1361 (2010).
58. A. Halle, V. Hornung, G. C. Petzold, C. R. Stewart, B. G. Monks, T. Reinheckel, K. A. Fitzgerald, E. Latz, K. J. Moore, D. T. Golenbock, The NALP3 inflammasome is involved in the innate immune response to amyloid-β. Nat. Immunol. 9, 857-865 (2008).
59. T. Kawai, S. Akira, Pathogen recognition with Toll-like receptors. Curr. Opin. Immunol. 17, 338-344 (2005).
60. T. Kawai, S. Akira, The role of pattern-recognition receptors in innate immunity: Update on Toll-like receptors. Nat. Immunol. 11, 373-384 (2010).
61. T. Kawai, S. Akira, Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity 34, 637-650 (2011).
62. C. R. Stewart, L. M. Stuart, K. Wilkinson, J. M. Van Gils, J. Deng, A. Halle, K. J. Rayner, L. Boyer, R. Zhong, W. A. Frazier, A. Lacy-Hulbert, J. El Khoury, D. T. Golenbock, K. J. Moore, CD36 ligands promote sterile inflammation through assembly of a Toll-like receptor 4 and 6 heterodimer. Nat. Immunol. 11, 155-161 (2010).
63. S. Lehnardt, Innate immunity and neuroinflammation in the CNS: The role of microglia in Toll-like receptor-mediated neuronal injury. Glia 58, 253-263 (2010).
64. E. G. Reed-Geaghan, J. C. Savage, A. G. Hise, G. E. Landreth, CD14 and toll-like receptors 2 and 4 are required for fibrillar Aβ-stimulated microglial activation. J. Neurosci. 29, 11982-11992 (2009).
65. 1-42 and delay the cognitive decline in a mouse model of Alzheimer's disease. J. Neurosci. 28, 5784-5793 (2008).
66. S. Walter, M. Letiembre, Y. Liu, H. Heine, B. Penke, W. Hao, B. Bode, N. Manietta, J. Walter, W. Schulz-Schuffer, K. Fassbender, Role of the toll-like receptor 4 in neuroinflammation in Alzheimer's disease. Cell. Physiol. Biochem. 20, 947-956 (2007).
67. C. Kim, D. H. Ho, J. E. Suk, S. You, S. Michael, J. Kang, S. Joong Lee, E. Masliah, D. Hwang, H. J. Lee, S. J. Lee, Neuron-released oligomeric α-synuclein is an endogenous agonist of TLR2 for paracrine activation of microglia. Nat. Commun. 4, 1562 (2013).
68. K. Cheng, X. Wang, S. Zhang, H. Yin, Discovery of small-molecule inhibitors of the TLR1/TLR2 complex. Angew. Chem. Int. Ed. Engl. 51, 12246-12249 (2012).
69. M. R. Dasu, A. C. Riosvelasco, I. Jialal, Candesartan inhibits Toll-like receptor expression and activity both in vitro and in vivo. Atherosclerosis 202, 76-83 (2009).
70. E. Angot, J. A. Steiner, C. Hansen, J. Y. Li, P. Brundin, Are synucleinopathies prion-like disorders? Lancet Neurol. 9, 1128-1138 (2010).
71. H. Braak, J. R. Bohl, C. M. Müller, U. Rüb, R. A. De Vos, K. Del Tredici, Stanley Fahn Lecture 2005: The staging procedure for the inclusion body pathology associated with sporadic Parkinson's disease reconsidered. Mov. Disord. 21, 2042-2051 (2006).
72. H. Braak, R. A. De Vos, J. Bohl, K. Del Tredici, Gastric α-synuclein immunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson's disease-related brain pathology. Neurosci. Lett. 396, 67-72 (2006).
73. H. Braak, K. Del Tredici, Invited article: Nervous system pathology in sporadic Parkinson disease. Neurology 70, 1916-1925 (2008).
74. H. Braak, U. Rüb, W. P. Gai, K. Del Tredici, Idiopathic Parkinson's disease: Possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. J. Neural Transm. 110, 517-536 (2003).
75. R. E. Burke, W. T. Dauer, J. P. Vonsattel, A critical evaluation of the Braak staging scheme for Parkinson's disease. Ann. Neurol. 64, 485-491 (2008).
76. D. W. Dickson, H. Uchikado, H. Fujishiro, Y. Tsuboi, Evidence in favor of Braak staging of Parkinson's disease. Mov. Disord. 25(Suppl. 1), S78-S82 (2010).
77. K. A. Jellinger, Critical evaluation of the Braak staging scheme for Parkinson's disease. Ann. Neurol. 67, 550 (2010).
78. A. N. Sacino, M. Brooks, M. A. Thomas, A. B. McKinney, N. H. McGarvey, N. J. Rutherford, C. Ceballos-Diaz, J. Robertson, T. E. Golde, B. I. Giasson, Amyloidogenic α-synuclein seeds do not invariably induce rapid, widespread pathology in mice. Acta Neuropathol. 127, 645-665 (2014).
79. K. C. Luk, V. Kehm, J. Carroll, B. Zhang, P. O'Brien, J. Q. Trojanowski, V. M. Lee, Pathological α-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science 338, 949-953 (2012).
80. K. C. Luk, V. M. Kehm, B. Zhang, P. O'Brien, J. Q. Trojanowski, V. M. Lee, Intracerebral inoculation of pathological α-synuclein initiates a rapidly progressive neurodegenerative α-synucleinopathy in mice. J. Exp. Med. 209, 975-986 (2012).
81. H. T. Tran, C. H. Chung, M. Iba, B. Zhang, J. Q. Trojanowski, K. C. Luk, V. M. Lee, α-Synuclein immunotherapy blocks uptake and templated propagation of misfolded α-synuclein and neurodegeneration. Cell Rep. 7, 2054-2065 (2014).
82. A. N. Sacino, M. Brooks, A. B. McKinney, M. A. Thomas, G. Shaw, T. E. Golde, B. I. Giasson, Brain injection of α-synuclein induces multiple proteinopathies, gliosis, and a neuronal injury marker. J. Neurosci. 34, 12368-12378 (2014).
83. A. N. Sacino, M. Brooks, M. A. Thomas, A. B. McKinney, S. Lee, R. W. Regenhardt, N. H. McGarvey, J. I. Ayers, L. Notterpek, D. R. Borchelt, T. E. Golde, B. I. Giasson, Intramuscular injection of α-synuclein induces CNS α-synuclein pathology and a rapid-onset motor phenotype in transgenic mice. Proc. Natl. Acad. Sci. U. S. A. 111, 10732-10737 (2014).
84. A. N. Sacino, M. Brooks, N. H. McGarvey, A. B. McKinney, M. A. Thomas, Y. Levites, Y. Ran, T. E. Golde, B. I. Giasson, Induction of CNS α-synuclein pathology by fibrillar and non-amyloidogenic recombinant α-synuclein. Acta Neuropathol. Commun. 1, 38 (2013).
85. A. Recasens, B. Dehay, J. Bové, I. Carballo-Carbajal, S. Dovero, A. Pérez-Villalba, P. O. Fernagut, J. Blesa, A. Parent, C. Perier, I. Fariñas, J. A. Obeso, E. Bezard, M. Vila, Lewy body extracts from Parkinson disease brains trigger α-synuclein pathology and neurodegeneration in mice and monkeys. Ann. Neurol. 75, 351-362 (2014).
86. E. G. McGeer, A. Klegeris, P. L. McGeer, Inflammation, the complement system and the diseases of aging. Neurobiol. Aging 26(Suppl. 1), 94-97 (2005).
87. P. L. McGeer, E. G. McGeer, Inflammation and the degenerative diseases of aging. Ann. N. Y. Acad. Sci. 1035, 104-116 (2004).
88. P. L. McGeer, E. G. McGeer, Glial reactions in Parkinson's disease. Mov. Disord. 23, 474-483 (2008).
89. M. E. Lull, M. L. Block, Microglial activation and chronic neurodegeneration. Neurotherapeutics 7, 354-365 (2010).
90. C. A. Colton, D. M. Wilcock, Assessing activation states in microglia. CNS Neurol. Disord. Drug Targets 9, 174-191 (2010).
91. M. Sawada, A. Suzumura, H. Hosoya, T. Marunouchi, T. Nagatsu, Interleukin-10 inhibits both production of cytokines and expression of cytokine receptors in microglia. J. Neurochem. 72, 1466-1471 (1999).
92. T. Kawai, S. Akira, Toll-like receptor downstream signaling. Arthritis Res. Ther. 7, 12-19 (2005).
93. Y. Kumagai, O. Takeuchi, S. Akira, Pathogen recognition by innate receptors. J. Infect. Chemother. 14, 86-92 (2008).
94. H. Kumar, T. Kawai, S. Akira, Pathogen recognition by the innate immune system. Int. Rev. Immunol. 30, 16-34 (2011).
95. M. S. Lee, Y. J. Kim, Signaling pathways downstream of pattern-recognition receptors and their cross talk. Annu. Rev. Biochem. 76, 447-480 (2007).
96. S. J. Lee, S. Lee, Toll-like receptors and inflammation in the CNS. Curr. Drug Targets Inflamm. Allergy 1, 181-191 (2002).
97. M. B. Watson, F. Richter, S. K. Lee, L. Gabby, J. Wu, E. Masliah, R. B. Effros, M. F. Chesselet, Regionally-specific microglial activation in young mice overexpressing human wildtype alpha-synuclein. Exp. Neurol. 237, 318-334 (2012).
98. C. Roodveldt, A. Labrador-Garrido, E. Gonzalez-Rey, C. C. Lachaud, T. Guilliams, R. Fernandez-Montesinos, A. Benitez-Rondan, G. Robledo, A. Hmadcha, M. Delgado, C. M. Dobson, D. Pozo, Preconditioning of microglia by α-synuclein strongly affects the response induced by toll-like receptor (TLR) stimulation. PLOS One 8, e79160 (2013).
99. G. Codolo, N. Plotegher, T. Pozzobon, M. Brucale, I. Tessari, L. Bubacco, M. De Bernard, Triggering of inflammasome by aggregated α-synuclein, an inflammatory response in synucleinopathies. PLOS One 8, e55375 (2013).
100. T. Trotta, C. Porro, R. Calvello, M. A. Panaro, Biological role of Toll-like receptor-4 in the brain. J. Neuroimmunol. 268, 1-12 (2014).
101. A. Oblak, R. Jerala, Toll-like receptor 4 activation in cancer progression and therapy. Clin. Dev. Immunol. 2011, 609579 (2011).
102. J. J. Jin, H. D. Kim, J. A. Maxwell, L. Li, K. Fukuchi, Toll-like receptor 4-dependent upregulation of cytokines in a transgenic mouse model of Alzheimer's disease. J. Neuroinflammation 5, 23 (2008).
103. K. J. Doorn, T. Moors, B. Drukarch, W. Van De Berg, P. J. Lucassen, A. M. Van Dam, Microglial phenotypes and toll-like receptor 2 in the substantia nigra and hippocampus of incidental Lewy body disease cases and Parkinson's disease patients. Acta Neuropathol. Commun. 2, 90 (2014).
104. 1 receptor blockade ameliorates brain inflammation. Neuropsychopharmacology 36, 857-870 (2011).
105. A. Dunne, N. A. Marshall, K. H. Mills, TLR based therapeutics. Curr. Opin. Pharmacol. 11, 404-411 (2011).
106. M. Gambuzza, N. Licata, E. Palella, D. Celi, V. Foti Cuzzola, D. Italiano, S. Marino, P. Bramanti, Targeting Toll-like receptors: Emerging therapeutics for multiple sclerosis management. J. Neuroimmunol. 239, 1-12 (2011).
107. E. J. Hennessy, A. E. Parker, L. A. O'Neill, Targeting Toll-like receptors: Emerging therapeutics? Nat. Rev. Drug Discov. 9, 293-307 (2010).
108. M. C. Michel, C. Foster, H. R. Brunner, L. Liu, A systematic comparison of the properties of clinically used angiotensin II type 1 receptor antagonists. Pharmacol. Rev. 65, 809-848 (2013).
109. T. N. Grammatopoulos, T. F. Outeiro, B. T. Hyman, D. G. Standaert, Angiotensin II protects against α-synuclein toxicity and reduces protein aggregation in vitro. Biochem. Biophys. Res. Commun. 363, 846-851 (2007).
110. B. Joglar, J. Rodriguez-Pallares, A. I. Rodriguez-Perez, P. Rey, M. J. Guerra, J. L. Labandeira-Garcia, The inflammatory response in the MPTP model of Parkinson's disease is mediated by brain angiotensin: Relevance to progression of the disease. J. Neurochem. 109, 656-669 (2009).
111. J. Rodriguez-Pallares, J. A. Parga, B. Joglar, M. J. Guerra, J. L. Labandeira-Garcia, Mitochondrial ATP-sensitive potassium channels enhance angiotensin-induced oxidative damage and dopaminergic neuron degeneration. Relevance for agingassociated susceptibility to Parkinson's disease. Age 34, 863-880 (2012).
112. 1 receptor blockers as treatments for inflammatory brain disorders. Clin. Sci. 123, 567-590 (2012).
113. 1 receptor blockers ameliorate inflammatory stress: A beneficial effect for the treatment of brain disorders. Cell. Mol. Neurobiol. 32, 667-681 (2012).
114. 1 receptors ameliorates stress, anxiety, brain inflammation and ischemia: Therapeutic implications. Psychoneuroendocrinology 36, 1-18 (2011).
115. B. Villar-Cheda, A. Dominguez-Meijide, B. Joglar, A. I. Rodriguez-Perez, M. J. Guerra, J. L. Labandeira-Garcia, Involvement of microglial RhoA/Rho-kinase pathway activation in the dopaminergic neuron death. Role of angiotensin via angiotensin type 1 receptors. Neurobiol. Dis. 47, 268-279 (2012).
116. T. N. Grammatopoulos, F. Ahmadi, S. M. Jones, M. W. Fariss, J. A. Weyhenmeyer, W. M. Zawada, Angiotensin II protects cultured midbrain dopaminergic neurons against rotenone-induced cell death. Brain Res. 1045, 64-71 (2005).
117. T. N. Grammatopoulos, S. M. Jones, F. A. Ahmadi, B. R. Hoover, L. D. Snell, J. Skoch, V. V. Jhaveri, A. M. Poczobutt, J. A. Weyhenmeyer, W. M. Zawada, Angiotensin type 1 receptor antagonist losartan, reduces MPTP-induced degeneration of dopaminergic neurons in substantia nigra. Mol. Neurodegener. 2, 1 (2007).
118. M. Platten, S. Youssef, E. M. Hur, P. P. Ho, M. H. Han, T. V. Lanz, L. K. Phillips, M. J. Goldstein, R. Bhat, C. S. Raine, R. A. Sobel, L. Steinman, Blocking angiotensinconverting enzyme induces potent regulatory T cells and modulates TH1- and TH17-mediated autoimmunity. Proc. Natl. Acad. Sci. U. S. A. 106, 14948-14953 (2009).
119. T. V. Lanz, Z. Ding, P. P. Ho, J. Luo, A. N. Agrawal, H. Srinagesh, R. Axtell, H. Zhang, M. Platten, T. Wyss-Coray, L. Steinman, Angiotensin II sustains brain inflammation in mice via TGF-β. J. Clin. Invest. 120, 2782-2794 (2010).
120. D. V. Erbe, K. Gartrell, Y. L. Zhang, V. Suri, S. J. Kirincich, S. Will, M. Perreault, S. Wang, J. F. Tobin, Molecular activation of PPARγ by angiotensin II type 1-receptor antagonists. Vascul. Pharmacol. 45, 154-162 (2006).
121. P. Garrido-Gil, B. Joglar, A. I. Rodriguez-Perez, M. J. Guerra, J. L. Labandeira-Garcia, Involvement of PPAR-γ in the neuroprotective and anti-inflammatory effects of angiotensin type 1 receptor inhibition: Effects of the receptor antagonist telmisartan and receptor deletion in a mouse MPTP model of Parkinson's disease. J. Neuroinflammation 9, 38 (2012).
122. 1-receptor blocker and PPAR-γ agonist, reduces lesion volume and improves motor and memory function after traumatic brain injury in mice. Neuropsychopharmacology 37, 2817-2829 (2012).
123. S. C. Benson, R. Iguchi, C. I. Ho, K. Yamamoto, T. W. Kurtz, Inhibition of cardiovascular cell proliferation by angiotensin receptor blockers: Are all molecules the same? J. Hypertens. 26, 973-980 (2008).
124. B. I. Giasson, K. Uryu, J. Q. Trojanowski, V. M. Lee, Mutant and wild type human α-synucleins assemble into elongated filaments with distinct morphologies in vitro. J. Biol. Chem. 274, 7619-7622 (1999).
125. K. A. Maguire-Zeiss, C. I. Wang, E. Yehling, M. A. Sullivan, D. W. Short, X. Su, G. Gouzer, L. A. Henricksen, C. A. Wuertzer, H. J. Federoff, Identification of human α-synuclein specific single chain antibodies. Biochem. Biophys. Res. Commun. 349, 1198-1205 (2006).
126. S. G. Daniele, A. A. Edwards, K. A. Maguire-Zeiss, Isolation of cortical microglia with preserved immunophenotype and functionality from murine neonates. J. Vis. Exp., e51005 (2014).
127. M. Noursadeghi, J. Tsang, T. Haustein, R. F. Miller, B. M. Chain, D. R. Katz, Quantitative imaging assay for NF-κB nuclear translocation in primary human macrophages. J. Immunol. Methods 329, 194-200 (2008).
128. J. W. Fuseler, D. M. Merrill, J. A. Rogers, M. B. Grisham, R. E. Wolf, Analysis and quantitation of NF-[kappa]B nuclear translocation in tumor necrosis factor alpha (TNF-[alpha]) activated vascular endothelial cells. Microsc. Microanal. 12, 269-276 (2006).